U.K. Professional Services Stock News

AstraZeneca share performance snapshot after recent moves AstraZeneca (LSE:AZN) has attracted attention after a recent 0.7% daily share price decline, following a run of positive returns over the past week, month, and past 3 months. See our latest analysis for AstraZeneca. That 0.7% daily share price decline sits against a stronger backdrop, with a 10.85% 3 month share price return and a 33.3% 1 year total shareholder return suggesting momentum has been building rather than fading. If...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

The United Kingdom's stock market has faced challenges recently, with the FTSE 100 index declining amid weak trade data from China, signaling ongoing global economic uncertainties. Despite these broader market fluctuations, there remains a segment of the investment landscape that continues to intrigue investors: penny stocks. Often associated with smaller or newer companies, these stocks can offer potential growth opportunities and affordability when backed by solid financials.

If you are wondering whether Glencore is attractively priced or starting to look expensive, its recent share moves and valuation checks offer some useful clues. The stock last closed at £4.53, with returns of 8.0% over 7 days, 20.5% over 30 days, 10.7% year to date and 27.9% over 1 year. The 3 year return stands at a 5.2% decline and the 5 year return at 109.2%. Recent news coverage has focused on Glencore's position in global commodities markets and how investor sentiment around resources...

Rentokil Initial plc's ( LON:RTO ) price-to-earnings (or "P/E") ratio of 44.7x might make it look like a strong sell...

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index closing lower due to weak trade data from China, highlighting concerns over global economic recovery. In such a climate, identifying undervalued stocks that may be trading below their fair value can offer potential opportunities for investors seeking to navigate these uncertain times.

As the United Kingdom's FTSE 100 index faces downward pressure due to weak trade data from China and global economic uncertainties, investors are keenly observing how these factors impact market dynamics. In such a volatile environment, growth companies with high insider ownership may offer an intriguing proposition, as insider confidence can often indicate potential resilience and long-term value amidst broader market challenges.

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices slipping due to weak trade data from China, highlighting global economic interdependencies. Despite these broader market uncertainties, investors may find opportunities in penny stocks—an investment area that remains relevant for those seeking potential growth in smaller or less-established companies. By focusing on penny stocks with strong financials and clear growth trajectories,...

As the United Kingdom's FTSE 100 index experiences a downturn, influenced by weak trade data from China and declining commodity prices, investors are increasingly looking beyond blue-chip stocks to uncover potential opportunities in the market. In this environment, identifying promising small-cap stocks like B.P. Marsh & Partners becomes crucial, as these companies often offer unique growth prospects that may not be immediately impacted by broader global economic challenges.

In recent weeks, the UK market has faced challenges, with the FTSE 100 index experiencing declines amid weak trade data from China and falling commodity prices. As global economic uncertainties persist, investors may find value in dividend stocks that offer consistent income streams and potential resilience during market fluctuations.

Anyone interested in Venture Life Group plc ( LON:VLG ) should probably be aware that the Co-Founder, Jeremy Anthony...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Spirax Group fair value estimate is UK£66.01 Spirax Group's...

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors can...

Unilever (LSE:ULVR) is back in focus after recent share moves that leave the stock modestly negative over the past month and the past 3 months, prompting investors to reassess its current valuation and fundamentals. See our latest analysis for Unilever. At the latest share price of £47.44, Unilever’s short term share price returns have been weak, with a 30 day share price return of a 1.89% decline and a 90 day share price return of a 5.79% decline. Its 5 year total shareholder return of...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Today we're going to take a look at the well-established Halma plc ( LON:HLMA ). The company's stock saw a decent share...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Oxford Nanopore Technologies plc's ( LON:ONT ) price-to-sales (or "P/S") ratio of 6.6x might make it look like a sell...

Insiders who bought Surface Transforms Plc ( LON:SCE ) stock in the last 12 months were richly rewarded last week. The...

There's no doubt that investing in the stock market is a truly brilliant way to build wealth. But if when you choose to...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

When close to half the companies in the Tobacco industry in the United Kingdom have price-to-sales ratios (or "P/S...

If you are wondering whether AstraZeneca shares are offering fair value at current levels, this article walks through what the numbers actually say about the stock. With the share price at £142.16 and returns of 4.6% over 7 days, 5.2% over 30 days, 4.6% year to date, 32.3% over 1 year, 30.0% over 3 years and 110.0% over 5 years, recent performance gives important context for any view on value. Recent headlines around AstraZeneca have kept the company firmly on investors' radars, including...

It is hard to get excited after looking at DCC's (LON:DCC) recent performance, when its stock has declined 12% over the...